Key result
Collaborative care for depression in patients with comorbid diabetes or CHD yielded a net QALY gain of 0.04 at an incremental cost of £16,123 per QALY gained over 24 months.
Why the study?
Is collaborative care cost-effective compared to usual care for treating depression in patients with comorbid diabetes or coronary heart disease?
Population
387 adults with persistent depressive symptoms and comorbid coronary heart disease and/or type 1 or 2…
Comparison
Collaborative care consisting of evidence-based… vs Usual care.
Design
Other
Follow-up
24 months (extrapolated)
Authors
Loading...
May support collaborative care consideration below UK threshold; leaves open confirmation via longer-term RCTs with narrower CIs.
RCT (n=387)
Yes
Is collaborative care cost-effective compared to usual care for treating depression in patients with comorbid diabetes or coronary heart disease?
Effect estimate: Cost per QALY gained £16 123
Collaborative care for depression in patients with comorbid diabetes or CHD is potentially cost-effective over the long term, with an estimated cost per QALY gained below the £20,000 threshold.
Camacho et al. (2016) conducted an RCT in Depression with comorbid diabetes or coronary heart disease (n=387). Collaborative care vs. Usual care was evaluated on Incremental cost-effectiveness ratio (cost per quality-adjusted life year (QALY)) (Cost per QALY gained £16 123). Collaborative care for depression in patients with comorbid diabetes or CHD yielded a net QALY gain of 0.04 at an incremental cost of £16,123 per QALY gained over 24 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: